Impact of denosumab on bone mass in cancer patients
Ursa Brown-Glaberman, Alison T StopeckUniversity of Arizona Cancer Center, Tucson, AZ, USAAbstract: Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important...
Guardado en:
Autores principales: | Brown-Glaberman U, Stopeck AT |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/78823999925b406a81c169e57d1323fd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
por: Stopeck AT, et al.
Publicado: (2012) -
The Treatment for a Patient with Cancer of Unknown Primary: A Case Report
por: QingTao Ni MD, et al.
Publicado: (2021) -
Retraction notice to 'Astragalus polysaccharide promotes proliferation and osteogenic differentiation of bone mesenchymal stem cells by down-regulation of microRNA-152' [Biomed. Pharmacother. 115 (2019) 108927]
por: Qiang Li, et al.
Publicado: (2021) -
NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines
por: North WG, et al.
Publicado: (2015) -
Impact of the chronic disease self-management program (CDSMP) on self-perceived frailty condition: the EU-EFFICHRONIC project
por: Sabrina Zora, et al.
Publicado: (2021)